title: A histomorphometric comparison of Bio-Oss alone versus Bio-Oss and platelet-derived growth factor for sinus augmentation: a postsurgical assessment.
abstract: The purpose of this study was to assess vital bone formation at 4 to 5 months and 7 to 9 months following sinus augmentation with anorganic bovine bone matrix (ABBM) with and without recombinant human platelet-derived growth factor (rhPDGF). Twenty-four subjects received bilateral sinus elevation surgery with ABBM on one side and ABBM and rhPDGF on the contralateral side. Twelve patients had core sampling at 4 to 5 months and 12 patients at 7 to 9 months postoperatively. In subjects with cores taken at 4 to 5 months, mean vital bone, connective tissue, and residual graft were 11.8%, 54.1%, and 33.6%, respectively, with ABBM alone. Cores of sinuses filled with ABBM and rhPDGF showed mean 21.1% vital bone, 51.4% connective tissue, and 24.8% residual graft. Paired t test showed a statistically significant difference in vital bone. In cores taken at 7 to 9 months, the values for ABBM alone and ABBM + rhPDGF were 21.4% vs 19.5% vital bone, 28.4% vs 44.2% connective tissue, and 40.3% residual graft vs 35.5%. There was no statistically significant difference in vital bone at 7 to 9 months after surgery. Test and control groups showed clinically acceptable levels of vital bone both at 4 to 5 months and 7 to 9 months postsurgery. However, vital bone formation was significantly greater in the 4- to 5-month sections of ABBM + rhPDGF vs the Bio-Oss alone. In the 7- to 9-month specimens, this difference disappeared. More rapid formation of vital bone with the addition of rhPDGF may allow for earlier implant placement.
authors.affiliation: Department of Periodontology and Implant Dentistry, New York University College of Dentistry, New York, NY 10019, USA. dr.froum@verizon.net
authors.forename: Stuart J
authors.initials: SJ
authors.lastname: Froum
authors.forename: Stephen
authors.initials: S
authors.lastname: Wallace
authors.forename: Sang-Choon
authors.initials: SC
authors.lastname: Cho
authors.forename: Edwin
authors.initials: E
authors.lastname: Rosenburg
authors.forename: Scott
authors.initials: S
authors.lastname: Froum
authors.forename: Robert
authors.initials: R
authors.lastname: Schoor
authors.forename: Patrick
authors.initials: P
authors.lastname: Mascarenhas
authors.forename: Dennis P
authors.initials: DP
authors.lastname: Tarnow
authors.forename: Patricia
authors.initials: P
authors.lastname: Corby
authors.forename: Nicolas
authors.initials: N
authors.lastname: Elian
authors.forename: Stefan
authors.initials: S
authors.lastname: Fickl
authors.forename: John
authors.initials: J
authors.lastname: Ricci
authors.forename: Bin
authors.initials: B
authors.lastname: Hu
authors.forename: Timothy
authors.initials: T
authors.lastname: Bromage
authors.forename: Ismael
authors.initials: I
authors.lastname: Khouly
mesh_terms: D020341:Absorbable Implants; D000077214:Becaplermin; D001857:Bone Matrix / Q000637:transplantation*; D018786:Bone Substitutes / Q000627:therapeutic use*; D003094:Collagen; D003238:Connective Tissue / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008437:Maxilla / Q000473:pathology; D008567:Membranes, Artificial; D008875:Middle Aged; D008903:Minerals / Q000627:therapeutic use*; D010012:Osteogenesis / Q000187:drug effects; D059745:Piezosurgery; D011446:Prospective Studies; D020574:Proto-Oncogene Proteins c-sis / Q000627:therapeutic use*; D011994:Recombinant Proteins; D016037:Single-Blind Method; D059546:Sinus Floor Augmentation / Q000379:methods*; D016896:Treatment Outcome
chemical_list: C106416:Bio-Gide; C077540:Bio-Oss; D018786:Bone Substitutes; D008567:Membranes, Artificial; D008903:Minerals; D020574:Proto-Oncogene Proteins c-sis; D011994:Recombinant Proteins; D000077214:Becaplermin; D003094:Collagen